89 related articles for article (PubMed ID: 9526572)
1. Design, synthesis, and evaluation of the multidrug resistance-reversing activity of D-glucose mimetics of hapalosin.
Dinh TQ; Smith CD; Du X; Armstrong RW
J Med Chem; 1998 Mar; 41(6):981-7. PubMed ID: 9526572
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of hapalosin and analogs as MDR-reversing agents.
O'Connell CE; Salvato KA; Meng Z; Littlefield BA; Schwartz CE
Bioorg Med Chem Lett; 1999 Jun; 9(11):1541-6. PubMed ID: 10386932
[TBL] [Abstract][Full Text] [Related]
3. A practical total synthesis of hapalosin, a 12-membered cyclic depsipeptide with multidrug resistance-reversing activity, by employing improved segment coupling and macrolactonization.
Palomo C; Oiarbide M; García JM; González A; Pazos R; Odriozola JM; Bañuelos P; Tello M; Linden A
J Org Chem; 2004 Jun; 69(12):4126-34. PubMed ID: 15176838
[TBL] [Abstract][Full Text] [Related]
4. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
[TBL] [Abstract][Full Text] [Related]
5. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activities of hapalosin derivatives with modification at the C12 position.
Kashihara N; To-e S; Nakamura K; Umezawa K; Yamamura S; Nishiyama S
Bioorg Med Chem Lett; 2000 Jan; 10(2):101-3. PubMed ID: 10673089
[TBL] [Abstract][Full Text] [Related]
7. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance-modifying components in human plasma with potential clinical significance.
Mülder HS; Pinedo HM; Timmer AT; Rao BR; Lankelma J
J Exp Ther Oncol; 1996 Jan; 1(1):13-22. PubMed ID: 9414384
[TBL] [Abstract][Full Text] [Related]
9. Total synthesis and conformational studies of hapalosin, N-desmethylhapalosin and 8-deoxyhapalosin.
Wagner B; Gonzalez GI; Tran Hun Dau ME; Zhu J
Bioorg Med Chem; 1999 May; 7(5):737-47. PubMed ID: 10400327
[TBL] [Abstract][Full Text] [Related]
10. Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid.
Kim HS; Min YD; Choi CH
Biochem Biophys Res Commun; 2001 Apr; 283(1):64-71. PubMed ID: 11322768
[TBL] [Abstract][Full Text] [Related]
11. Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance.
Muñoz-Martínez F; Lu P; Cortés-Selva F; Pérez-Victoria JM; Jiménez IA; Ravelo AG; Sharom FJ; Gamarro F; Castanys S
Cancer Res; 2004 Oct; 64(19):7130-8. PubMed ID: 15466210
[TBL] [Abstract][Full Text] [Related]
12. Effects of multidrug resistance-related ATP-binding-cassette transporter proteins on the cytoskeletal activity of cytochalasins.
Berger W; Micksche M; Elbling L
Exp Cell Res; 1997 Dec; 237(2):307-17. PubMed ID: 9434626
[TBL] [Abstract][Full Text] [Related]
13. Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators.
Coburger C; Wollmann J; Krug M; Baumert C; Seifert M; Molnár J; Lage H; Hilgeroth A
Bioorg Med Chem; 2010 Jul; 18(14):4983-90. PubMed ID: 20598550
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
15. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells.
Gollapudi S; Kim CH; Tran BN; Sangha S; Gupta S
Cancer Chemother Pharmacol; 1997; 40(2):150-8. PubMed ID: 9182837
[TBL] [Abstract][Full Text] [Related]
16. Thieno[2,3-b]pyridines--a new class of multidrug resistance (MDR) modulators.
Krauze A; Grinberga S; Krasnova L; Adlere I; Sokolova E; Domracheva I; Shestakova I; Andzans Z; Duburs G
Bioorg Med Chem; 2014 Nov; 22(21):5860-70. PubMed ID: 25311564
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells.
Wang F; Jiang X; Yang DC; Elliott RL; Head JF
Anticancer Res; 2000; 20(2A):799-808. PubMed ID: 10810357
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
van der Kolk DM; de Vries EG; van Putten WJ; Verdonck LF; Ossenkoppele GJ; Verhoef GE; Vellenga E
Clin Cancer Res; 2000 Aug; 6(8):3205-14. PubMed ID: 10955805
[TBL] [Abstract][Full Text] [Related]
20. Diversity-oriented asymmetric synthesis of hapalosin: construction of three small C9/C4/C3-modified hapalosin analogue libraries.
Dai CF; Cheng F; Xu HC; Ruan YP; Huang PQ
J Comb Chem; 2007; 9(3):386-94. PubMed ID: 17358084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
